RSS Feeds
No Hepatitis After Treatment with a Modified Factor IX Concentrate in Previously Untreated Hemophiliacs
- PIER MANNUCCIO MANNUCCI, M. D.;
- MASSIMO MORFINI, M.D.;
- LOREDANA GATTI, M.D.;
- DANIELA RAFANELLI, M.D.;
- MASSIMO COLOMBO, M.D.;
- DARIO GEROLDI, M.D.;
- MONICA EINARSSON, Ph.D.; and
- ALESSANDRO R. ZANETTI, Ph.D.
- Maggiore Hospital and University of Milan, Milan, Italy
- Hemophilia Center, Florence, Italy
- University of Pavia, Pavia, Italy
- University of Uppsala, Uppsala, Sweden
Excerpt
Post-transfusion hepatitis is a serious and frequent complication in patients treated with clotting factor concentrates made from plasma pooled from a large number of donors. The occurrence is close to 100% in hemophiliacs who have not previously received blood or blood derivatives (first-exposure patients) (1-3). Recently, several manufacturers of concentrate have developed physical or chemical methods that remove or inactivate viruses with little or no loss of clotting factor activity. One manufacturer has added hydrophobic interaction chromatography on octanohydrazide-agarose to the regular fractionation process of a commercial concentrate of clotting factors II, VII, IX, and X (4). In-vitro studies have
Acknowledgments
ACKNOWLEDGMENTS: The authors thank Dr. P. B. A. Kernoff, Royal Free Hospital, London, England, for helpful discussion.
Article and Author Information
-
Grant support: in part by a grant from Assessorato Sanita, Regione Lombardia.
-
▸Requests for reprints should be addressed to Pier Mannuccio Manucci, M.D.; Via Pace 9; 20122 Milano, Italy.
